Mednow Announces Filing of Final Prospectus for up to $35,000,000 Initial Public Offering Led by Gravitas Securities, Eight Capital and Stifel GMP

Short article material


VANCOUVER, British Columbia — Mednow Inc. (“Mednow” or the “Company”) is delighted to reveal that it has actually submitted and acquired an invoice for a last prospectus with the securities regulative authorities in the provinces of Alberta, British Columbia, Saskatchewan, Manitoba, and Ontario (the “SellingJurisdictions”), in connection with its going public (“IPO”) of a minimum of 3,703,703 and approximately 5,185,185 systems (the “Units”) at a rate of $6.75 per System (“Offering Price”) for overall gross earnings of a minimum of $25,000,000 and approximately an optimum of $35,000,000. Each System includes one Class A typical share (each a, “Common Share”) and half of one Typical Share purchase necessitate (each whole warrant a, “Warrant”). Each Warrant entitles its holder to buy one Typical Share at a rate of $8.50 for a duration of 24 months following the closing of the IPO.

The closing of the IPO and the listing of the Typical Shares of Mednow on the TSX Endeavor Exchange (“TSXV”), under the trading sign “MNOW” has actually been conditionally authorized, based on satisfying traditional TSXV listing requirements.

Short article material

The distribute is led by Gravitas Securities Inc., 8 Capital and Stifel Nicolaus Canada Inc. and consists of Canaccord Genuity Corp. and Raymond James Ltd. (jointly, the “Agents”).

In connection with the IPO, the Business has actually likewise approved the Agents an alternative (the “Over-Allotment Option”), exercisable in entire or in part, for a duration of 1 month following the IPO’s closing date, to offer up to an extra 740,740 Systems at the Offering Rate, to cover over-allotments, if any, and for market stabilization functions. If the Over-Allotment Choice is worked out completely, the aggregate gross earnings of the IPO will be $40,000,000.

The net earnings from the IPO will be utilized to money its innovation advancement, customer acquisition efforts and for basic business functions.

A copy of the last prospectus can be seen on SEDAR (

No securities regulative authority has actually either authorized or disapproved the contents of this press release. This press release does not make up a deal to offer or the solicitation of a deal to purchase, nor will there be any sale or any approval of a deal to purchase these securities in any jurisdiction in which such deal, solicitation or sale would be illegal.

These securities have actually not been, nor will they be, signed up under the United States Securities Act of 1933, as changed, and might not be used or offered in the United States without registration or an appropriate exemption from the registration requirements of that Act. This press release does not make up a market of these securities in the United States.


Mednow is a health care innovation business providing virtual gain access to with remarkable care. Created with gain access to and quality care in mind, offers virtual care with benefit and through an interdisciplinary method to health care that is concentrated on the client experience. Drug store services consist of complimentary at-home shipment of medications, a user-friendly user interface for simple upload, transfer and refill of prescriptions, access to health care specialists through an instinctive chat experience, a specialized PillSmart™ system that packages prescriptions and vitamins by date and time, along with access to telemedicine virtual care.

To read more check out:

View source variation on


Financier Relations Contact:
Marc Charbin

Media Contact:
Jalila Singerff
Jive PR + Digital


Jobber Wiki author Frank Long contributed to this report.